CA3089559A1 - Spiro-lactam nmda receptor modulators and uses thereof - Google Patents
Spiro-lactam nmda receptor modulators and uses thereof Download PDFInfo
- Publication number
- CA3089559A1 CA3089559A1 CA3089559A CA3089559A CA3089559A1 CA 3089559 A1 CA3089559 A1 CA 3089559A1 CA 3089559 A CA3089559 A CA 3089559A CA 3089559 A CA3089559 A CA 3089559A CA 3089559 A1 CA3089559 A1 CA 3089559A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- group
- independently selected
- substituents
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862624218P | 2018-01-31 | 2018-01-31 | |
| US62/624,218 | 2018-01-31 | ||
| US201862718107P | 2018-08-13 | 2018-08-13 | |
| US62/718,107 | 2018-08-13 | ||
| PCT/US2019/016098 WO2019152678A1 (en) | 2018-01-31 | 2019-01-31 | Spiro-lactam nmda receptor modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3089559A1 true CA3089559A1 (en) | 2019-08-08 |
Family
ID=65494516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3089559A Pending CA3089559A1 (en) | 2018-01-31 | 2019-01-31 | Spiro-lactam nmda receptor modulators and uses thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210047324A1 (https=) |
| EP (1) | EP3746442A1 (https=) |
| JP (2) | JP2021512109A (https=) |
| KR (1) | KR20200115610A (https=) |
| CN (1) | CN112218866A (https=) |
| AU (1) | AU2019215049A1 (https=) |
| BR (1) | BR112020015666A2 (https=) |
| CA (1) | CA3089559A1 (https=) |
| CL (1) | CL2020001990A1 (https=) |
| IL (1) | IL276330A (https=) |
| MX (1) | MX2020008106A (https=) |
| PE (1) | PE20211455A1 (https=) |
| PH (1) | PH12020551140A1 (https=) |
| SG (1) | SG11202007251XA (https=) |
| WO (1) | WO2019152678A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA032649B1 (ru) | 2013-01-29 | 2019-06-28 | Аптиникс Инк. | Спиролактамные модуляторы nmda-рецептора и их применение |
| MX385336B (es) | 2016-08-01 | 2025-03-18 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactam y uso de los mismos. |
| WO2018026782A1 (en) | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| SG10202101055VA (en) | 2016-08-01 | 2021-03-30 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof |
| JP2019527232A (ja) | 2016-08-01 | 2019-09-26 | アプティニックス インコーポレイテッド | スピロ−ラクタムｎｍｄａ修飾因子及びこれを用いた方法 |
| CN112204031B (zh) | 2018-01-31 | 2024-05-24 | 元羿生物科技(香港)有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
| BR122023024273A2 (pt) | 2018-02-27 | 2024-02-20 | Incyte Corporation | Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos |
| WO2019222677A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| GEP20237548B (en) | 2018-07-05 | 2023-10-10 | Incyte Corp | Fused pyrazine derivatives as a2a /a2b inhibitors |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
| WO2024054919A1 (en) * | 2022-09-08 | 2024-03-14 | Tenacia Biotechnology (Hong Kong) Co., Limited | Spiro-lactam nmda receptor modulators and uses thereof |
| US20250115551A1 (en) * | 2023-10-03 | 2025-04-10 | Revolution Medicines, Inc. | Synthesis of ras inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011003015A (es) * | 2008-09-18 | 2011-11-18 | Univ Northwestern | Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos. |
| TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| CN105037492A (zh) * | 2010-02-11 | 2015-11-11 | 西北大学 | 二级结构稳定化的nmda受体调节剂及其用途 |
| CN102267995A (zh) * | 2010-06-04 | 2011-12-07 | 艾琪康医药科技（上海）有限公司 | 一种制备二氮杂螺环化合物的方法 |
| EA032649B1 (ru) * | 2013-01-29 | 2019-06-28 | Аптиникс Инк. | Спиролактамные модуляторы nmda-рецептора и их применение |
| KR20150110586A (ko) * | 2013-01-29 | 2015-10-02 | 노렉스, 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| SG11201505862TA (en) * | 2013-01-29 | 2015-08-28 | Naurex Inc | Spiro-lactam nmda receptor modulators and uses thereof |
| SG11201505942YA (en) * | 2013-01-29 | 2015-08-28 | Naurex Inc | Spiro-lactam nmda receptor modulators and uses thereof |
| KR20150110787A (ko) * | 2013-01-29 | 2015-10-02 | 노렉스, 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| HUE049481T2 (hu) * | 2015-04-03 | 2020-09-28 | Recurium Ip Holdings Llc | Spirociklusos vegyületek |
| WO2017201285A1 (en) * | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| BR112018073663A2 (pt) * | 2016-05-19 | 2019-04-30 | Aptinyx Inc. | moduladores de receptores nmda spiro-lactâmicos e seus usos |
| SG10202101055VA (en) * | 2016-08-01 | 2021-03-30 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof |
| AR110988A1 (es) * | 2017-02-21 | 2019-05-22 | Sanofi Sa | Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados |
| JP2022092387A (ja) * | 2020-12-10 | 2022-06-22 | キヤノン株式会社 | 画像形成装置 |
-
2019
- 2019-01-31 US US16/966,176 patent/US20210047324A1/en not_active Abandoned
- 2019-01-31 JP JP2020541807A patent/JP2021512109A/ja active Pending
- 2019-01-31 CN CN201980018351.6A patent/CN112218866A/zh active Pending
- 2019-01-31 CA CA3089559A patent/CA3089559A1/en active Pending
- 2019-01-31 EP EP19706076.7A patent/EP3746442A1/en not_active Withdrawn
- 2019-01-31 BR BR112020015666-3A patent/BR112020015666A2/pt not_active Application Discontinuation
- 2019-01-31 WO PCT/US2019/016098 patent/WO2019152678A1/en not_active Ceased
- 2019-01-31 MX MX2020008106A patent/MX2020008106A/es unknown
- 2019-01-31 PE PE2020001149A patent/PE20211455A1/es unknown
- 2019-01-31 KR KR1020207024903A patent/KR20200115610A/ko not_active Withdrawn
- 2019-01-31 AU AU2019215049A patent/AU2019215049A1/en not_active Abandoned
- 2019-01-31 SG SG11202007251XA patent/SG11202007251XA/en unknown
-
2020
- 2020-07-27 IL IL276330A patent/IL276330A/en unknown
- 2020-07-28 PH PH12020551140A patent/PH12020551140A1/en unknown
- 2020-07-30 CL CL2020001990A patent/CL2020001990A1/es unknown
-
2023
- 2023-11-10 JP JP2023192455A patent/JP2024019396A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019215049A1 (en) | 2020-09-17 |
| IL276330A (en) | 2020-09-30 |
| EP3746442A1 (en) | 2020-12-09 |
| PH12020551140A1 (en) | 2021-05-31 |
| CN112218866A (zh) | 2021-01-12 |
| BR112020015666A2 (pt) | 2021-02-23 |
| WO2019152678A1 (en) | 2019-08-08 |
| SG11202007251XA (en) | 2020-08-28 |
| PE20211455A1 (es) | 2021-08-05 |
| MX2020008106A (es) | 2020-09-25 |
| CL2020001990A1 (es) | 2021-03-26 |
| KR20200115610A (ko) | 2020-10-07 |
| JP2024019396A (ja) | 2024-02-09 |
| US20210047324A1 (en) | 2021-02-18 |
| JP2021512109A (ja) | 2021-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3089559A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| US12084444B2 (en) | Spiro-lactam NMDA modulators and methods of using same | |
| US11376250B2 (en) | Spiro-lactam NMDA receptor modulators and uses thereof | |
| US11578072B2 (en) | Spiro-lactam NMDA receptor modulators and uses thereof | |
| EP3490994B1 (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| EP3490992B1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| WO2019152685A1 (en) | Spiro-lactam nmda receptor modulators and methods of using same | |
| WO2019152688A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| WO2019152696A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| WO2024054919A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| WO2019152681A1 (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220916 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20240801 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250124 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260106 |